<DOC>
	<DOCNO>NCT02443337</DOCNO>
	<brief_summary>The main purpose study evaluate safety activity study drug know LY3023414 combination necitumumab participant metastatic squamous non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study LY3023414 Necitumumab Squamous Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm squamous advanced NSCLC ( Stage IV ) . Participants must progress one prior line platinumbased chemotherapy advance metastatic setting . Measurable disease measure response evaluation criterion solid tumor ( RECIST ) criteria v 1.1 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 . Able swallow study drug whole . Adequate organ function . Women childbearing potential must negative serum urine pregnancy test perform ≤ 7 day prior start treatment . Women childbearing potential men partner childbearing potential must use effective birth control measure treatment 3 month follow completion study treatment . Participants receive &gt; 1 prior line chemotherapy advance metastatic setting . ( Immunotherapy consider line chemotherapy . ) Prior treatment PI3K/mTOR inhibitor , epidermal growth factor receptor ( EGFR ) inhibitor , and/or necitumumab . History brain metastasis unless irradiate ≥ 2 week prior first study treatment stable without requirement corticosteroid . Have serious preexist medical condition . Have insulindependent diabetes mellitus . Participants type 2 diabetes mellitus eligible adequate control blood glucose level obtain oral antidiabetic . Women pregnant breastfeeding . Clinically significant electrolyte imbalance ≥ Grade 2 . Currently receive treatment therapeutic dos warfarin sodium . Low molecular weight heparin oral Xa inhibitor allow . Have initiate treatment bisphosphonates approve receptor activator nuclear factor kappaB ligand ( RANKL ) target agent ( e.g . denosumab ) ≤ 28 day prior Day 1 Cycle 1 . Concurrent serious infection require parenteral antibiotic therapy . Have second primary malignancy judgment investigator Medical Monitor may affect interpretation result . Have active , known fungal , bacterial , and/or know viral infection . History arterial venous embolism within 3 month prior study enrollment . If embolism occur &gt; 3 &lt; 6 month , participant eligible provide appropriate treatment accord institutional standard care ensure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>